| Name | Title | Contact Details |
|---|---|---|
John Lamoureux |
Director, Global IT Infrastructure and Security | Profile |
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion`s rich, relatable database of more than a petabyte of biological images generated in-house on the company`s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients` lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes.
SCOLR Pharma Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.